Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118225) titled 'To evaluate the safety and efficacy of apalorito volrelizumab combined with chemotherapy as neoadjuvant therapy for locally advanced cervical cancer' on Feb. 3.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shandong Provincial Hospital
Condition:
Cervical cancer
Intervention:
Experimental group:Paclitaxel 150mg/m^2 + Cisplatin 70mg/m^2, intravenous drip, administered on the first day
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2025-05-13
Target Sample Size: Experimental group:29;
Countries of Recruitment:
China
To know more, visit https://www.chi...